Adrienne M. Gilligan
YOU?
Author Swipe
View article: Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in <i>RET</i> -Mutant Medullary Thyroid Cancer
Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in <i>RET</i> -Mutant Medullary Thyroid Cancer Open
Background: Progression-free survival (PFS) may not fully capture the impact of treatment on patients, especially in cancers with longer natural histories and thus, could be complemented by robust measures of patient-reported…
View article: Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC
Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC Open
These PROs, combined with the established efficacy and safety profile of selpercatinib, further support the use of first-line selpercatinib as a standard of care and highlight the importance of early and comprehensive genomic testing in pa…
View article: Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer
Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer Open
Background This psychometric analysis generated evidence to support the use of the Functional Assessment of Cancer Therapy item GP5 (GP5) as a measure of tolerability and confirms the appropriateness of categorizing “high side-effect burde…
View article: Assessing Side-Effect Bother, Burden, and Tolerability: A Qualitative Study Exploring the Content Validity of the Functional Assessment of Cancer Therapy – Item GP5
Assessing Side-Effect Bother, Burden, and Tolerability: A Qualitative Study Exploring the Content Validity of the Functional Assessment of Cancer Therapy – Item GP5 Open
Purpose Patient-reported measures of overall side effect burden, such as the Functional Assessment of Cancer Therapy- item GP5 (GP5), can be used to inform the tolerability of cancer treatments and be included as an endpoint in clinical tr…
View article: Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial
Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial Open
A majority of patients with RET-driven cancers improved or remained stable on most QLQ-C30 domains, demonstrating favorable health-related quality of life as measured by the QLQ-C30 during long-term treatment with selpercatinib.
View article: Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with <i>RET</i> -altered solid tumors in the US
Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with <i>RET</i> -altered solid tumors in the US Open
Three-year incremental PMPM cost estimates suggest a modest impact on payer-budgets associated with introduction of tumor-agnostic selpercatinib treatment.
View article: Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001
Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001 Open
Selpercatinib is indicated for locally advanced/metastatic RET-activated solid tumors after progression or following prior systemic therapies. Until the recently published data from LIBRETTO-431 and LIBRETTO-531, there were limited effecti…
View article: Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma Open
Background Despite the availability of new treatments, multiple myeloma (MM) is an incurable cancer with nearly all patients relapsing and undergoing multiple lines of treatment. Performing head-to-head comparisons of all treatment options…
View article: Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma Open
Background: Despite the availability of new treatments, multiple myeloma (MM) is an incurable cancer with nearly all patients relapsing and undergoing multiple lines of treatment. Performing head-to-head comparisons of all treatment option…
View article: Health-Related Quality of Life and Pain with Selinexor in Patients with Advanced Dedifferentiated Liposarcoma
Health-Related Quality of Life and Pain with Selinexor in Patients with Advanced Dedifferentiated Liposarcoma Open
Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials & methods: HRQoL was assessed at baseline and day 1 of each cycle using the Europe…
View article: Development of a Prognostic Factor Index Among Women With HR+/HER2− Metastatic Breast Cancer in a Community Oncology Setting
Development of a Prognostic Factor Index Among Women With HR+/HER2− Metastatic Breast Cancer in a Community Oncology Setting Open
View article: Comparison of healthcare costs among patients with non‐valvular atrial fibrillation treated with warfarin who switched to a novel oral anticoagulant
Comparison of healthcare costs among patients with non‐valvular atrial fibrillation treated with warfarin who switched to a novel oral anticoagulant Open
To compare all-cause healthcare costs among non-valvular atrial fibrillation (NVAF) patients who switched from warfarin to novel oral anticoagulants (NOAC). Adult NVAF patients who switched from warfarin to dabigatran, rivaroxaban or apixa…
View article: Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis
Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis Open
Objectives: To describe ixekizumab treatment patterns, all-cause healthcare utilization, and costs among psoriasis patients. Methods: Adults diagnosed with psoriasis having ≥1 ixekizumab claim were selected from MarketScan
View article: Healthcare Resource Utilization among Non-Valvular Atrial Fibrillation Patients Who Switched from Warfarin to a Novel Oral Anti-Coagulant
Healthcare Resource Utilization among Non-Valvular Atrial Fibrillation Patients Who Switched from Warfarin to a Novel Oral Anti-Coagulant Open
Among patients with non-valvular atrial fibrillation (NVAF), switching from warfarin to novel oral anticoagulants (NOACs) is common, yet clarifying the differences in the effect of NOACs on all-cause healthcare resource utilization (HCRU) …
View article: Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin
Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin Open
Background: This is one of the first head-to-head real-world evidence studies comparing stroke-related and bleed-related healthcare and resource utilization (HCRU) and costs among non-valvular atrial fibrillation (NVAF) patients ini…
View article: Comparative cost and clinical effectiveness of clostridial collagenase ointment for chronic dermal ulcers
Comparative cost and clinical effectiveness of clostridial collagenase ointment for chronic dermal ulcers Open
Chronic dermal ulcers affect approximately 2.4–4.5 million people in the USA and are associated with loss of function, decreased quality of life and significant economic burden. Debridement is a critical component of wound care involving r…
View article: All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin
All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin Open
View article: Economic analysis and budget impact of clostridial collagenase ointment compared with medicinal honey for treatment of pressure ulcers in the US
Economic analysis and budget impact of clostridial collagenase ointment compared with medicinal honey for treatment of pressure ulcers in the US Open
The results of these economic analyses suggest that CCO is a cost-effective, economically dominant alternative to MH in the treatment of patients with PUs in the hospital outpatient department setting.
View article: Comparative Effectiveness of Clostridial Collagenase Ointment to Medicinal Honey for Treatment of Pressure Ulcers
Comparative Effectiveness of Clostridial Collagenase Ointment to Medicinal Honey for Treatment of Pressure Ulcers Open
Objective: Compare enzymatic debridement using clostridial collagenase ointment (CCO) with autolytic debridement using medicinal honey in the hospital outpatient setting for treating pressure ulcers (PUs). Approach: Retrospec…
View article: Difficult-to-heal wounds of mixed arterial/venous and venous etiology: a cost-effectiveness analysis of extracellular matrix
Difficult-to-heal wounds of mixed arterial/venous and venous etiology: a cost-effectiveness analysis of extracellular matrix Open
ECM yielded better clinical outcomes at a slightly lower cost in patients with mixed A/V and VLUs. ECM is an effective treatment for wound healing and should be considered for use in the management of mixed A/V and VLUs.
View article: Erratum to: Cost‐effectiveness of clostridial collagenase ointment on wound closure in patients with diabetic foot ulcers: economic analysis of results from a multicenter, randomized, open‐label trial
Erratum to: Cost‐effectiveness of clostridial collagenase ointment on wound closure in patients with diabetic foot ulcers: economic analysis of results from a multicenter, randomized, open‐label trial Open
[This corrects the article DOI: 10.1186/s13047-015-0065-x.].
View article: Cost‐effectiveness of becaplermin gel on wound healing of diabetic foot ulcers
Cost‐effectiveness of becaplermin gel on wound healing of diabetic foot ulcers Open
We sought to determine the long‐term cost effectiveness (payer's perspective) of becaplermin gel plus good wound care (BGWC) vs. good wound care (GWC) alone in terms of wound healing and risk of amputation in patients with diabetic foot ul…
View article: Cost‐effectiveness of clostridial collagenase ointment on wound closure in patients with diabetic foot ulcers: economic analysis of results from a multicenter, randomized, open‐label trial
Cost‐effectiveness of clostridial collagenase ointment on wound closure in patients with diabetic foot ulcers: economic analysis of results from a multicenter, randomized, open‐label trial Open
Background Approximately 10%–15% of people with diabetes develop at least one foot ulcer during their lifetime. Treatment of diabetic foot ulcers (DFUs) represents a significant economic burden. Enzymatic debridement with clostridial colla…